PILOT TRIAL OF RITUXIMAB IN REFRACTORY MYASTHENIA GRAVIS

利妥昔单抗治疗难治性重症肌无力的试点试验

• 批准号: 7605796
• 负责人: RUP TANDAN
• 金额: $ 1.45万
• 依托单位: UNIVERSITY OF VERMONT & ST AGRIC COLLEGE
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-01 至 2008-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7605796
• 关键词: Computer Retrieval of Information on Scientific Projects Database; Disease; Feasibility Studies; Funding; Grant; Institution; Label; Literature; Myasthenia Gravis; Patients; Phase; Refractory; Refractory Disease; Research; Research Personnel; Resources; Safety; Source; United States National Institutes of Health; Week; Widespread Disease; pilot trial; rituximab

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. There is preliminary evidence in the literature that treatment of MG patients with rituximab is likely to be of benefit. This will be an open-label, Phase I-II, four-center 36-week feasibility study of rituximab in 10 consecutive MG patients with active symptomatic and refractory generalized disease. The primary objective is to examine the effects of rituximab on disease activity in MG patients with refractory disease. The secondary objective is to determine the safety and tolerability of rituximab in these patients.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 文献中有初步证据表明，利妥昔单抗患者的治疗可能有益。 这将是一项开放标签，I-II期，四中三周的可行性研究，利妥昔单抗在10例连续有症状和难治性概括性疾病的MG患者中进行。 主要目的是检查利妥昔单抗对难治性疾病患者疾病活性的影响。 次要目标是确定利妥昔单抗在这些患者中的安全性和耐受性。